Consequently, a partial loss of neutralization against other wildtype SARS-CoV-2 strains or variants might be expected in the serum from KCONVAC-immunized individuals, but this needs to be studied further
Consequently, a partial loss of neutralization against other wildtype SARS-CoV-2 strains or variants might be expected in the serum from KCONVAC-immunized individuals, but this needs to be studied further. (5 or 10 g/dose) or placebo. The participants in the phase 2 trial were randomized to receive either KCONVAC (at 5 or 10 g/dose) or placebo […]